PERSPECTIVE3-5 min to read

Obesity is a growing problem

As global obesity rates rise, so too is expected spending on obesity-related healthcare.


Weight loss drugs have been the biggest story in the pharmaceutical sector over the past year. These treatments regulate blood sugar, commonly called glucagon-like peptide 1 (GLP-1) agonists. Ozempic is one of the most well-known brands, with many celebrities admitting to using it, from Elon Musk to Amy Schumer. Two companies at the forefront of developing these treatments are Eli Lilly and Novo Nordisk. It is estimated that together they make up 90% of the obesity treatment market.

Global obesity rates are steadily rising

Obesity rates globally and across select countries (%)


Source: World Health Organization (WHO). Data as of 2016 (published in 2021).

Of the 537 million diabetics worldwide, just 15% are in good control of their condition. Meanwhile, just 2% of the 764 million with obesity are treated medically.

Both Eli Lilly and Novo Nordisk are highly cash generative businesses, with large and growing research and development budgets, which should cement their market leadership. These innovations are causing a paradigm shift in the way that obesity and its related diseases are treated, with doctors offering more weight-centric treatment plans in the first instance.

Expected obesity-related healthcare spending up to 2050


Source: World Health Organization (WHO), Organization for Economic Co-operation and Development (OECD).

The opportunities stretch beyond glycaemic control and weight loss, with huge patient populations across related diseases all in need of treatments.

Existing global patient populations across potential treatment areas for GLP-1 drugs


Source: Capital Group, Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), World Obesity Federation.

Important information

This communication is marketing material. The views and opinions contained herein are those of the author(s) on this page, and may not necessarily represent views expressed or reflected in other Schroders communications, strategies or funds. This material is intended to be for information purposes only and is not intended as promotional material in any respect. The material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. It is not intended to provide and should not be relied on for accounting, legal or tax advice, or investment recommendations. Reliance should not be placed on the views and information in this document when taking individual investment and/or strategic decisions. Past performance is not a reliable indicator of future results. The value of an investment can go down as well as up and is not guaranteed. All investments involve risks including the risk of possible loss of principal. Information herein is believed to be reliable but Schroders does not warrant its completeness or accuracy. Some information quoted was obtained from external sources we consider to be reliable. No responsibility can be accepted for errors of fact obtained from third parties, and this data may change with market conditions. This does not exclude any duty or liability that Schroders has to its customers under any regulatory system. Regions/ sectors shown for illustrative purposes only and should not be viewed as a recommendation to buy/sell. The opinions in this material include some forecasted views. We believe we are basing our expectations and beliefs on reasonable assumptions within the bounds of what we currently know. However, there is no guarantee than any forecasts or opinions will be realised. These views and opinions may change. The content is issued by Schroder Investment Management Limited, 1 London Wall Place, London EC2Y 5AU. Registered No. 1893220 England. Authorised and regulated by the Financial Conduct Authority.